Vigil Neuroscience, Inc. (VIGL)
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
VIGL Insider Trading Activity
VIGL Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $48,970 | 4 | 100 |
Sells | $0 | 0 | 0 |
Related Transactions
| Magovcevic-Liebisch Ivana | President and CEO | 3 | $28,450 | 0 | $0 | $28,450 |
| Budd Haeberlein Samantha L. | director | 1 | $20,520 | 0 | $0 | $20,520 |
About Vigil Neuroscience, Inc.
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral …
Insider Activity of Vigil Neuroscience, Inc.
Over the last 12 months, insiders at Vigil Neuroscience, Inc. have bought $48,970 and sold $0 worth of Vigil Neuroscience, Inc. stock.
On average, over the past 5 years, insiders at Vigil Neuroscience, Inc. have bought $17.69M and sold $4,200 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Magovcevic-Liebisch Ivana (President and CEO) — $28,450. Budd Haeberlein Samantha L. (director) — $20,520.
The last purchase of 5,000 shares for transaction amount of $8,400 was made by Magovcevic-Liebisch Ivana (President and CEO) on 2024‑12‑19.
List of Insider Buy and Sell Transactions, Vigil Neuroscience, Inc.
| 2024-12-19 | Magovcevic-Liebisch Ivana | President and CEO | 5,000 0.0123% | $1.68 | $8,400 | +38.55% | ||
| 2024-12-19 | Budd Haeberlein Samantha L. | director | 12,000 0.0301% | $1.71 | $20,520 | +38.55% | ||
| 2024-12-18 | Magovcevic-Liebisch Ivana | President and CEO | 5,000 0.0124% | $1.67 | $8,350 | +36.97% | ||
| 2024-12-05 | Magovcevic-Liebisch Ivana | President and CEO | 5,000 0.0125% | $2.34 | $11,700 | -3.46% | ||
| 2023-11-20 | Magovcevic-Liebisch Ivana | President and CEO | 4,000 0.0114% | $3.75 | $15,000 | -6.85% | ||
| 2022-11-18 | Sale | Papapetropoulos Spyros | Chief Medical Officer | 300 0.001% | $14.00 | $4,200 | -27.54% | |
| 2022-05-16 | Thorp Clay | 14,893 0.0551% | $2.97 | $44,189 | +235.79% | |||
| 2022-05-05 | Thackaberry Evan | SVP, Head of Early Development | 1,500 0.0064% | $4.00 | $6,000 | +185.03% | ||
| 2022-05-03 | Ziolkowski Jennifer Lynn | Chief Financial Officer | 4,000 0.0149% | $3.77 | $15,098 | +163.16% | ||
| 2022-05-03 | Verni Christopher | General Counsel | 4,000 0.0148% | $3.77 | $15,074 | +163.16% | ||
| 2022-05-03 | Papapetropoulos Spyros | Chief Medical Officer | 4,000 0.0134% | $3.40 | $13,591 | +163.16% | ||
| 2022-05-02 | Magovcevic-Liebisch Ivana | President and CEO | 4,000 0.0141% | $3.61 | $14,439 | +160.99% | ||
| 2022-03-28 | Thorp Clay | 3,000 0.0114% | $7.20 | $21,604 | +25.92% | |||
| 2022-01-11 | Vitorovic Stefan | director | 1.68M 7.4164% | $14.00 | $23.45M | -24.96% | ||
| 2022-01-11 | Vida Ventures GP III, L.L.C. | 10 percent owner | 1.68M 7.4164% | $14.00 | $23.45M | -24.96% | ||
| 2022-01-11 | Booth Bruce | director | 535,000 2.3688% | $14.00 | $7.49M | -24.96% | ||
| 2022-01-11 | Atlas Venture Fund XII, L.P. | 10 percent owner | 535,000 2.3688% | $14.00 | $7.49M | -24.96% | ||
| 2022-01-11 | Thorp Clay | director | 265,000 1.1733% | $14.00 | $3.71M | -24.96% | ||
| 2022-01-11 | Northpond Ventures GP, LLC | 10 percent owner | 355,000 1.5718% | $14.00 | $4.97M | -24.96% |
Insider Historical Profitability
| Magovcevic-Liebisch Ivana | President and CEO | 222687 0.5447% | $449,827.74 | 5 | 0 | +77.07% |
| Budd Haeberlein Samantha L. | director | 12000 0.0294% | $24,240.00 | 1 | 0 | |
| Vitorovic Stefan | director | 5004393 12.2418% | $10.11M | 1 | 0 | <0.0001% |
| Vida Ventures GP III, L.L.C. | 10 percent owner | 5004393 12.2418% | $10.11M | 1 | 0 | <0.0001% |
| Booth Bruce | director | 4808896 11.7636% | $9.71M | 1 | 0 | <0.0001% |
Historical Insider Profitability vs. Competitors
$4,919,189 | 138 | 5.22% | $95.3M | |
$49,091,668 | 110 | 13.11% | $83.06M | |
$155,580,641 | 77 | -24.21% | $86.51M | |
$4,898,715 | 46 | 40.74% | $73.28M | |
$329,102,560 | 42 | 30.96% | $73.82M |
VIGL Institutional Investors: Active Positions
| Increased Positions | 30 | +51.72% | 3M | +12.36% |
| Decreased Positions | 23 | -39.66% | 5M | -16.14% |
| New Positions | 11 | New | 2M | New |
| Sold Out Positions | 12 | Sold Out | 3M | Sold Out |
| Total Postitions | 65 | +12.07% | 27M | -3.78% |
VIGL Ownership Change vs Market
Institutional Investor Ownership
| Atlas Venture Life Science Advisors, Llc | $11,790.00 | 12.42% | 5.84M | 0 | 0% | 2024-12-31 |
| Northpond Ventures, Llc | $8,513.00 | 8.97% | 4.21M | 0 | 0% | 2024-09-30 |
| Siren, L.L.C. | $4,022.00 | 4.24% | 1.99M | 0 | 0% | 2024-12-31 |
| Bvf Inc/Il | $3,664.00 | 3.86% | 1.81M | 0 | 0% | 2024-12-31 |
| Citadel Advisors Llc | $3,045.00 | 3.21% | 1.51M | +64,724 | +4.49% | 2024-12-31 |
| Sphera Funds Management Ltd. | $3,035.00 | 3.2% | 1.5M | -145,175 | -8.81% | 2024-12-31 |
| 683 Capital Management, Llc | $2,828.00 | 2.98% | 1.4M | +180,420 | +14.79% | 2024-12-31 |
| Vanguard Group Inc | $1,970.00 | 2.08% | 975,473 | +70,742 | +7.82% | 2024-12-31 |
| Ensign Peak Advisors, Inc | $1,420.00 | 1.5% | 703,116 | +97,580 | +16.11% | 2024-12-31 |
| Pivotal Bioventure Partners Investment Advisor Llc | $1,132.00 | 1.19% | 560,595 | 0 | 0% | 2024-12-31 |